Feasibility of Pediatric Contrast Sensitivity Test

描述（由申请人提供）：该STTR项目开发和评估了一种新的视觉对比敏感度临床测试，将适用于婴儿和不可识别的儿童和成人。这种条纹卡对比敏感度（SCCS）测试将是有用的，在定量描述患者的视觉功能与一系列的视觉障碍，在规划和以下的治疗和干预，在确定残疾的深度，并在评估新的治疗方法的好处。其潜在市场包括眼科医生，验光师和世界各地的其他眼科护理专家。在第1阶段，将评估SCCS试验的临床可行性，并确定其对临床实践的影响。临床可行性将通过确定其是否可用于测试大范围视觉表现的儿童来研究，包括正常新生儿和具有低视力和其他残疾的学龄患者。这将包括评估SCCS测试是否足够可靠用于临床使用，并通过确定年龄较大的低视力儿童，SCCS测试的对比敏感度结果是否与使用对比敏感度测试的“金标准”Pelli- Robson图表获得的结果一致。将通过检查SCCS测试结果与经充分验证的关于视力损害对患者生活影响的问卷调查结果之间的关系，研究测试对临床实践的影响。 同样在第1阶段，将确定生产SCCS测试用于商业销售给眼科医生和验光师的技术可行性，他们将在其诊所中使用该测试。技术工作将开发具体的方法，以生产精确校准和准确对比度值的SCCS卡，这些卡没有可能产生虚假结果的伪影， 临床实践，其足够耐用以在多年使用中保持无伪影，并且其对于临床医生来说价格合理。第2阶段的计划包括进行年龄标准化和其他测量，这些测量将指导临床医生解释个体患者的SCCS测试结果。第三阶段商业化计划包括扩大和生产SCCS测试及其协议，使其可用于世界各地的眼科护理专家。 公共卫生相关性：该项目开发并评估了一种新的视觉对比敏感度临床测试，该测试将适用于婴儿，无法辨认的儿童和残疾成人。这种条纹卡对比敏感度（SCCS）测试将是有用的，在定量描述患者的视觉功能与一系列的视觉障碍，在规划和以下的治疗和干预，在确定残疾的深度，并在评估新的治疗方法的好处。如果成功，这项临床测试将被世界各地的眼科医生、验光师和其他眼科护理专家使用。

DESCRIPTION (provided by applicant): This STTR project develops and assesses a new clinical test of visual contrast sensitivity that will work on infants and uninstructable children nd adults. This Stripe Card Contrast Sensitivity (SCCS) test would be useful in quantitatively describing the visual function of patients with a range of visual disorders, in planning and following treatments and interventions, in determining the depth of disability, and in assessing the benefits of new treatments. Its potential market includes ophthalmologists, optometrists and other eye care specialists around the world. In the Phase-1 year, the clinical feasibility of the SCCS test will be assessed and its impact on clinical practice will be established. The clinical feasibility will be investigated by determining whether it can be used to test children over a larg range of visual performance, including normal newborn infants and school-aged patients with low vision and other handicaps. This will include assessment of whether the SCCS test is reliable enough for clinical use, and by determining, on older low-vision children, whether the contrast sensitivity results for the SCCS test agree with those obtained using the "gold standard" for contrast sensitivity testing, the Pelli- Robson chart. The impact of the test on clinical practice will be studied by examining the relationship between SCCS test results and results of a well-validated questionnaire on the impact of vision impairment on the patient's life. Also in the Phase-1 year, the technical feasibility will be established of producing the SCCS test for commercial sale to ophthalmologists and optometrists who will use it in their clinics. Technical work will develop the specific methods to produce SCCS cards of precisely calibrated and accurate values of contrast, which are free of artifacts that could produce spurious results in clinical practice, which are durable enough to remain artifact-free over many years of use, and which are reasonably priced for the clinician. Plans for Phase-2 include performing age-norming and other measurements that will guide the clinician in interpreting the SCCS test results on an individual patient. Phase-3 commercialization plan includes scaling up and production of the SCCS test and its protocols making it available to eye care specialists around the world. PUBLIC HEALTH RELEVANCE: This project develops and evaluates a new clinical test of visual contrast sensitivity that will work on infants, uninstructable children and handicapped adults. This Stripe Card Contrast Sensitivity (SCCS) test would be useful in quantitatively describing the visual function of patients with a range of visual disorders, in planning and following treatments and interventions, in determining the depth of disability, and in assessing the benefits of new treatments. If it is successful, this clinical test will be used by ophthalmologists, optometrists and other eye care specialists around the world.